VAXCYTE, INC. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
VAXCYTE, INC. (PCVX) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $1.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2024-11-05
- VAXCYTE, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-09-30 was $1.00K.
- VAXCYTE, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-06-30 was $27.00K.
- VAXCYTE, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-03-31 was $22.00K.
- VAXCYTE, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-09-30 was $0.00.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month |
|---|---|---|---|
| 2024-09-30 | $1.00K 10-Q · filed 2024-11-05 | $28.00K derived: sum of 2 quarters · filed 2024-11-05 | $50.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $27.00K 10-Q · filed 2024-08-06 | $49.00K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $22.00K 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |